secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2026-08-05T11:05:22+00:00
Accession:  0001193125-26-333821
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint Q2 net loss $94.5M ($1.09/sh); cash $180M; LUGANO data expected August 2026
--------------------------------------------------------------------------------

- Net loss $94.5M vs $59.4M YoY; revenue $0.5M vs $5.3M.
- Cash and investments $180M as of June 30, 2026, down from $223M at March 31, 2026.
- LUGANO Phase 3 wet AMD topline data expected in August 2026; LUCIA data Q4 2026.
- DME Phase 3 trials COMO and CAPRI fully enrolled (over 480 patients); topline data Q4 2027.
- Appointed Tarek S. Hassan, M.D., as Chief Strategic Science Officer in July 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000119312526333821/0001193125-26-333821-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000119312526333821/eypt-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-333821

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer